Loading clinical trials...
Loading clinical trials...
A Single-center, Open-label, Single-dose Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C] HQP1351 After a Single Oral 30mg (100µCi) Dose in Healthy Chinese Male Subjects
Conditions
Interventions
[14C] HQP1351
Locations
1
China
The First Affiliated Hospital with Nanjing Medical University
Nanjing, China
Start Date
November 19, 2019
Primary Completion Date
January 13, 2020
Completion Date
January 13, 2020
Last Updated
September 8, 2021
NCT06514534
NCT05589896
NCT02790515
NCT03746054
NCT01667133
Lead Sponsor
Ascentage Pharma Group Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions